Series B brings in $15.3mm for ExThera

ExThera Medical Corp. (medical devices for bloodstream infections and pathogen-reduction in blood banking) raised $15.3mm through the sale of Series B preferred stock and the conversion of a convertible note. New investor Fresenius Medical Care Ventures led and was joined by returning shareholders. According to the Form D, 30 investors participated. The company will use the proceeds for US and European clinical trials, regulatory activities, and to scale manufacturing of its Seraph Microbind affinity blood filter, the only device of its kind for capturing and removing a broad range of sepsis-causing bacteria, viruses, toxins, and pro-inflammatory cytokines from whole blood.